LBRX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

LB Pharmaceuticals Inc Common Stock · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 35.01 USD
11.5% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 29.6% above the Trend Line and sits at 93.2% of its 52-week range. The latest completed week returned 11.5%, after a 9.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 48/100 conviction, while the latest news-sentiment score is 63/100. Near-term considerations: price is close to its 52-week high; earnings are due in 13d.

Setup score 65 out of 100
Latest Close 35.01 USD 24 Jul 2026
1W Return 11.5% latest completed week
4W Return 9.7% short-term follow-through
12W Return 11.4% quarterly tape
Trend Breadth 37.0% 17 of 46 weeks active
Volume Ratio 1.8x vs 13-week average
What is working
  • The trend backdrop is active with a 17-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 13 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 11.5% Latest completed week; four-week move 9.7%. Indicator stack 65/78 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 48/100 conviction; expected move 17.1%. News sentiment 63/100 54 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 29.6% above the Trend Line and sits at 93.2% of its 52-week range. The latest completed week returned 11.5%, after a 9.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8112-week average 0.75

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.81Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1313 reversal markers

No recent accumulation markers. 13 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 9.7% over four weeks, 11.4% over 12 weeks, and - over one year. The current trend has remained active for 17 consecutive weeks.

Performance by holding period

1W11.5%
4W9.7%
12W11.4%
26W46.4%
52W-
Active trend streak17 weeks
Active weeks in one year17
Trend breadth37.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.45Latest activity-pressure read.
Pressure change246.6%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 61% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength79/100Blend of value, momentum, and quality. Underlying universe rank 22; rank 1 is best.
Value64/100Relative valuation strength. Underlying universe rank 37; rank 1 is best.
Quality63/100Profitability and accounting quality. Underlying universe rank 38; rank 1 is best.
Momentum64/100Medium-term price momentum. Underlying universe rank 37; rank 1 is best.
Growth64/100Revenue and earnings growth. Underlying universe rank 37; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-7.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-48.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-42.6%
Net share repurchases relative to market value.
Shareholder yield
-42.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
8.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

LBRX shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 6.43, expected move of 17.1%, and Sharemaestro trend signal active.

Conviction48/100
Expected move17.1%
Put/call volume6.43
Pressure-85
Speculation11
Volatility93
Trend agreement2
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment63/100

Weighted news tone is positive across 54 relevant articles.

30 positive · 23 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move17.1%Nearest-chain priced movement where available.
52-week drawdown-4.3%Distance below the 52-week high.
13-week volatility5.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+25.4%Week of 17 Apr.
Worst week-10.3%Week of 30 Jan.
Latest week+11.5%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains7
Flat weeks0
Modest losses5
Sharp losses6
Recent vol5.0%13-week weekly-return volatility.
Base vol7.1%52-week weekly-return volatility.
Up/down split26/19Count of positive and negative weeks in the 52-week window.
Average skew6.2% / -4.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape62/100

Trend, activity pressure, participation, and risk combine to a 62/100 tape read.

 Indicator analysis59/100

Latest 12-week confirmation: trend 12/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.81; 13 reversal markers Factors67/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 95; Small Cap Core rank 45 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options35/100

LBRX shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 6.43, expected move of 17.1%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 17.1% Sentiment63/100

Weighted news tone is positive across 54 relevant articles.

LB Pharmaceuticals Inc $LBRX is Spruce Street Capital LP's 3rd Largest Position Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202635.01 USD11.5%27.01 USD23.50 USD0.45-2.1MOn
17 Jul 202631.41 USD-4.7%26.56 USD23.25 USD0.47-791.4KOn
10 Jul 202632.95 USD-1.4%26.22 USD23.06 USD0.49-1.4MOn
3 Jul 202633.43 USD4.7%25.75 USD22.83 USD0.32-1.3MOn
26 Jun 202631.92 USD6.4%25.29 USD22.58 USD0.13-3.1MOn
19 Jun 202630.00 USD5.6%24.82 USD22.35 USD-0.03-1.2MOn
12 Jun 202628.42 USD-0.4%24.33 USD22.16 USD0.05-935.0KOn
5 Jun 202628.53 USD2.0%23.88 USD22.00 USD0.31-797.3KOn
29 May 202627.97 USD-0.5%23.44 USD21.83 USD0.66-796.6KOn
22 May 202628.12 USD-5.2%23.05 USD21.66 USD0.98-878.6KOn
15 May 202629.66 USD-7.2%22.64 USD21.48 USD1.23-680.3KOn
8 May 202631.97 USD1.7%22.17 USD21.25 USD1.33-623.2KOn
1 May 202631.43 USD2.3%21.62 USD20.94 USD1.07-792.9KOn
24 Apr 202630.73 USD0.7%21.08 USD20.62 USD0.89-1.2MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.